Evidence mapPaperPMID 26459191Full record

Observational studyClinical cardiology2015

Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry.

Seth S Martin, Kamil F Faridi, Parag H Joshi, Michael J Blaha, Krishnaji R Kulkarni, Arif A Khokhar, Thomas M Maddox, Edward P Havranek, Peter P Toth, Fengming Tang and 2 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. The Association Between Hyperlipidemia and In-Hospital Outcomes in Takotsubo Cardiomyopathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

Seth S MartinJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Kamil F FaridiJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Parag H JoshiJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Michael J BlahaJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Krishnaji R KulkarniAtherotech Diagnostics Laboratory, Birmingham, Alabama.
Arif A KhokharNorthwest London Hospitals NHS Trust, London, United Kingdom.
Thomas M MaddoxVA Eastern Colorado Health Care System, Denver, Colorado.
Edward P HavranekUniversity of Colorado School of Medicine, Aurora, Colorado.
Peter P TothJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Fengming TangSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri.
John A SpertusSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri.
Steven R JonesJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.
Johns Hopkins University · USJohns Hopkins Medicine · USAC Diagnostics (United States) · USPeoria campus of the University of Illinois System · USRoyal London Hospital · GBSaint Luke's Hospital · USUniversity of Colorado Denver · USUniversity of Missouri–Kansas City · USVA Eastern Colorado Health Care System · US

Funding

PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$4.3M
CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$3.7M
SCCOR in Cardiac Dysfunction and DiseaseP50HL077113 · WASHINGTON UNIVERSITY · 2005 to 2005
$2.8M
NCATS NIH HHS UL1 TR001082NHLBI NIH HHS P50 HL 077113NHLBI NIH HHS P50 HL077113NHLBI NIH HHS T32 HL007024NHLBI NIH HHS T32 HL007227NHLBI NIH HHS T32HL007227NHLBI NIH HHS T32HL07024
6 · The paper itself

Abstract

backgroundRemnants are partially hydrolyzed, triglyceride-rich lipoproteins that, like other apolipoprotein B-containing lipoproteins, are atherogenic. Prior observational studies suggest paradoxically better outcomes in hypercholesterolemic patients who sustain an acute myocardial infarction (AMI), one of several known recurrent risk paradoxes. To date, the association of directly measured remnant lipoprotein cholesterol (RLP-C) with survival after an AMI has not been examined. HYPOTHESIS: Higher RLP-C levels may be paradoxically associated with lower mortality.

methodsWe examined 2465 AMI survivors in a prospective, 24-center US study of AMI outcomes. Lipoprotein cholesterol subfractions were directly measured by ultracentrifugation. RLP-C was defined as intermediate-density lipoprotein cholesterol (IDL-C) + very-low-density lipoprotein cholesterol subfraction 3 (VLDL3 -C). Given a linear relationship between RLP-C and mortality, we examined RLP-C by tertiles and continuously. Cox regression hazard ratios (HRs) were adjusted for the Global Registry of Acute Coronary Events (GRACE) score and 23 other covariates.

resultsParticipants were age 58 ± 12 years (mean ± SD), and 68% were men. After 2 years of follow-up, 226 (9%) participants died. The mortality proportion was 12.4% in the lowest tertile of RLP-C (0-15 mg/dL), 8.5% in the middle tertile (16-23 mg/dL), and 6.8% in the highest tertile (24-120 mg/dL; P < 0.001). A 1-SD increase in RLP-C (11 mg/dL) predicted a 24% lower adjusted risk of 2-year mortality (HR: 0.76, 95% confidence interval [CI]: 0.64-0.91). Similar results were found for a 1-SD increase in IDL-C (HR per 8 mg/dL: 0.80, 95% CI: 0.67-0.96), VLDL3 -C (HR per 4 mg/dL: 0.74, 95% CI: 0.61-0.89), and very-low-density lipoprotein cholesterol (VLDL-C; HR per 8 mg/dL: 0.69, 95% CI: 0.55-0.85).

conclusionsHigher RLP-C levels were associated with lower mortality 2 years after AMI despite rigorous adjustment for known confounders. Unknown protective factors or a lead-time bias likely explains the paradox.

Indexed as

AgedBiomarkersChi-Square DistributionCholesterolFemaleHumansHypercholesterolemiaKaplan-Meier EstimateLinear ModelsLipoproteinsMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsProspective StudiesProtective FactorsBiomarkersCholesterolLipoproteinsremnant-like particle cholesterolTriglycerides

Identifiers

PMID26459191
PMCPMC4715617
OpenAlexW2186472140

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.